To investigate DPP-4 inhibitors type dependent effects on antifibrotic miRNA and biomarkers.

Not Applicable

• Conditions: Type 2 diabetic patients

• Registration Number: JPRN-UMIN000019273
• Lead Sponsor: Kanazawa Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-08
• Study Completion: 2017-09-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

(1)Patient who have a history of allergy to Linagliptin or Sitagliptin. (2)Patients who have severe ketosis, diabetic coma, diabetic pre-coma, or type 1 diabetes (3)Patients who have severe infection, surgery, planned surgery, severe trauma. (4)Women who are pregnant, or possibility of pregnant, or wish to pregnant, or lactating. (5)Patients with transit disorder in the digestive tract or peptic ulcer and esophageal varix (this product may irritate affected area.) and patients whom physician judges as inappropriate (6)Patients with a predisposition to severe and habitual constipation (this product may exacerbate constipation) and patients whom physician judges as inappropriate (7)Patients who are considered unsuitable for inclusion by the attending physician.

Study & Design

• Study Type: Interventional
• Study Design: Not specified